Akari Therapeutics (NASDAQ:AKTX) Stock Price Crosses Below 200 Day Moving Average – Here’s Why

Akari Therapeutics, Plc (NASDAQ:AKTX) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.80 and traded as low as $1.02. Akari Therapeutics shares last traded at $1.10, with a volume of 57,287 shares.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on Akari Therapeutics in a research note on Tuesday. They issued a “sell” rating for the company.

Akari Therapeutics Stock Up 1.9 %

The firm has a 50 day simple moving average of $1.11 and a 200 day simple moving average of $1.80.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.